Tenofovir/FTC vs. Abacavir/3TC: Results from the ASSERT Study

Tenofovir/FTC produced higher rates of virologic suppression than abacavir/3TC; the two regimens led to similarly small increases in estimated glomerular filtration rate.

Comparisons of abacavir and tenofovir continue to be of great interest. In the open-label ASSERT study (sponsored by the manufacturer of abacavir), 392 HIV-infected, treatment-naive patients who tested negative for the HLA-B*5701 genotype were randomized to receive abacavir/3TC or tenofovir/FTC, each together with efavirenz. The primary endpoint was the 48-week change in estimated glomerular filtration rate (eGFR), calculated using the MDRD (Modification of Diet in Renal Disease) equation. Changes in biomarkers of tubular secretion were assessed as a secondary endpoint.

The adjusted mean change in eGFR was not significantly different between the two treatment groups (+0.22 mL/minute/1.73 m² for the abacavir/3TC group and +1.18 mL/minute/1.73…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Tenofovir/FTC vs. Abacavir/3TC: Results from the ASSERT Study

Topics

Reviewing Author